274 related articles for article (PubMed ID: 31079148)
1. Long-term proarrhythmic pharmacotherapy among patients with congenital long QT syndrome and risk of arrhythmia and mortality.
Weeke PE; Kellemann JS; Jespersen CB; Theilade J; Kanters JK; Hansen MS; Christiansen M; Marstrand P; Gislason GH; Torp-Pedersen C; Bundgaard H; Jensen HK; Tfelt-Hansen J
Eur Heart J; 2019 Oct; 40(37):3110-3117. PubMed ID: 31079148
[TBL] [Abstract][Full Text] [Related]
2. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
Lu HR; Yan GX; Gallacher DJ
J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
[TBL] [Abstract][Full Text] [Related]
3. Antidepressants and antipsychotics classified with torsades de pointes arrhythmia risk and mortality in older adults - a Swedish nationwide study.
Danielsson B; Collin J; Jonasdottir Bergman G; Borg N; Salmi P; Fastbom J
Br J Clin Pharmacol; 2016 Apr; 81(4):773-83. PubMed ID: 26574175
[TBL] [Abstract][Full Text] [Related]
4. Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors.
Grouthier V; Lebrun-Vignes B; Glazer AM; Touraine P; Funck-Brentano C; Pariente A; Courtillot C; Bachelot A; Roden DM; Moslehi JJ; Salem JE
Heart; 2018 Nov; 104(22):1859-1863. PubMed ID: 29720397
[TBL] [Abstract][Full Text] [Related]
5. Clinical characterization of men with long QT syndrome and torsades de pointes associated with hypogonadism: A review and pharmacovigilance study.
Salem JE; Bretagne M; Lebrun-Vignes B; Waintraub X; Gandjbakhch E; Hidden-Lucet F; Gougis P; Bachelot A; Funck-Brentano C;
Arch Cardiovasc Dis; 2019 Nov; 112(11):699-712. PubMed ID: 31477476
[TBL] [Abstract][Full Text] [Related]
6. A case series of drug-induced long QT syndrome and Torsade de Pointes.
Tong KL; Lau YS; Teo WS
Singapore Med J; 2001 Dec; 42(12):566-70. PubMed ID: 11989578
[TBL] [Abstract][Full Text] [Related]
7. Drug use and torsades de pointes cardiac arrhythmias in Sweden: a nationwide register-based cohort study.
Danielsson B; Collin J; Nyman A; Bergendal A; Borg N; State M; Bergfeldt L; Fastbom J
BMJ Open; 2020 Mar; 10(3):e034560. PubMed ID: 32169926
[TBL] [Abstract][Full Text] [Related]
8. Acquired long QT syndrome from stress cardiomyopathy is associated with ventricular arrhythmias and torsades de pointes.
Madias C; Fitzgibbons TP; Alsheikh-Ali AA; Bouchard JL; Kalsmith B; Garlitski AC; Tighe DA; Estes NA; Aurigemma GP; Link MS
Heart Rhythm; 2011 Apr; 8(4):555-61. PubMed ID: 21146632
[TBL] [Abstract][Full Text] [Related]
9. [QTc-prolonging drugs and the risk of sudden death].
Reingardiene D; Vilcinskaite J
Medicina (Kaunas); 2007; 43(4):347-53. PubMed ID: 17485963
[TBL] [Abstract][Full Text] [Related]
10. High prevalence of risk factors in elderly patients using drugs associated with acquired torsades de pointes chronically in Colombia.
Moreno-Gutiérrez PA; Gaviria-Mendoza A; Cañón MM; Machado-Alba JE
Br J Clin Pharmacol; 2016 Aug; 82(2):504-11. PubMed ID: 27060989
[TBL] [Abstract][Full Text] [Related]
11. Deep learning analysis of electrocardiogram for risk prediction of drug-induced arrhythmias and diagnosis of long QT syndrome.
Prifti E; Fall A; Davogustto G; Pulini A; Denjoy I; Funck-Brentano C; Khan Y; Durand-Salmon A; Badilini F; Wells QS; Leenhardt A; Zucker JD; Roden DM; Extramiana F; Salem JE
Eur Heart J; 2021 Oct; 42(38):3948-3961. PubMed ID: 34468739
[TBL] [Abstract][Full Text] [Related]
12. Predicting the Unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes.
Schwartz PJ; Woosley RL
J Am Coll Cardiol; 2016 Apr; 67(13):1639-1650. PubMed ID: 27150690
[TBL] [Abstract][Full Text] [Related]
13. Drugs that cause Torsades de pointes and increase the risk of sudden cardiac death.
Wolbrette DL
Curr Cardiol Rep; 2004 Sep; 6(5):379-84. PubMed ID: 15306095
[TBL] [Abstract][Full Text] [Related]
14. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
Lawrence CL; Pollard CE; Hammond TG; Valentin JP
J Pharmacol Toxicol Methods; 2005; 52(1):46-59. PubMed ID: 15975832
[TBL] [Abstract][Full Text] [Related]
15. Drug-induced QT prolongation and sudden death.
Del Rosario ME; Weachter R; Flaker GC
Mo Med; 2010; 107(1):53-8. PubMed ID: 20222297
[TBL] [Abstract][Full Text] [Related]
16. Reckless administration of QT interval-prolonging agents in elderly patients with drug-induced torsade de pointes.
Jackobson G; Carmel NN; Lotan D; Kremer A; Justo D
Z Gerontol Geriatr; 2018 Jan; 51(1):41-47. PubMed ID: 27878411
[TBL] [Abstract][Full Text] [Related]
17. Ketoconazole induced torsades de pointes without concomitant use of QT interval-prolonging drug.
Mok NS; Lo YK; Tsui PT; Lam CW
J Cardiovasc Electrophysiol; 2005 Dec; 16(12):1375-7. PubMed ID: 16403073
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of the risk factors for QT prolongation and associated drug-drug interactions in a cohort of medical inpatients.
Khan Q; Ismail M; Haider I; Ali Z
J Formos Med Assoc; 2019 Jan; 118(1 Pt 1):109-115. PubMed ID: 29458991
[TBL] [Abstract][Full Text] [Related]
19. Electrocardiographic Parameters Indicating Worse Evolution in Patients with Acquired Long QT Syndrome and Torsades de Pointes.
Kukla P; Jastrzębski M; Fijorek K; Stec S; Bryniarski L; Czarnecka D; Baranchuk A
Ann Noninvasive Electrocardiol; 2016 Nov; 21(6):572-579. PubMed ID: 27018992
[TBL] [Abstract][Full Text] [Related]
20. Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit.
Jacobson I; Carlsson L; Duker G
J Pharmacol Toxicol Methods; 2011; 63(1):40-6. PubMed ID: 20451633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
